The International Quotidian Dialysis Registry is a global collaborative initiative designed to study practices and outcomes associated with more intensive hemodialysis prescriptions.
What is Quotidian Dialysis?
The term “quotidian” denotes an event that recurs daily. In the context of hemodialysis, it has traditionally referred to daily, or at least frequent hemodialysis treatments. The original stated objective of the IQDR was to study outcomes associated with hemodialysis prescriptions with a treatment frequency of at least 5 sessions per week. As more alternative hemodialysis prescriptions have emerged, the scope of the IQDR has broadened to include prescriptions that are not strictly “quotidian”. These include long intermittent hemodialysis (daytime or nocturnal - e.g., > 6 hours, three or more sessions per week) as well as daily hemofiltration. As the menu of alternative hemodialysis schedules grows, the IQDR will strive to collect available data and report on patient outcomes associated with these therapies.
Aims and Scope of the IQDR
The primary objective of the IQDR is to evaluate patient outcomes and associated hemodialysis prescription practices, among patients receiving more intensive hemodialysis prescriptions. Primary outcomes of interest include:
1) patient survival
2) hospitalization
3) vascular access outcomes
4) technique survival
5) transplant outcomes
Drawing on data from individual dialysis facilities, national registries, commercial, and other research databases, patients receiving more intensive hemodialysis will be compared to patients receiving other forms of renal replacement therapy, including conventional HD, peritoneal dialysis, and kidney transplants. Primary study designs will include prospective and retrospective cohort studies.
The IQDR will also serve to describe prescription patterns and patient characteristics across participating countries.
Who Can Participate in the IQDR?
The IQDR collects data from individual dialysis facilities that offer hemodialysis treatments that are longer than 5.5 hours per session, or greater than 4 sessions per week, and includes nocturnal (during sleep) and short-daily hemodialysis, both in-centre (in a dialysis facility) and in the home setting. Participants from any country or practice-setting are welcome. National registries, commercial and research databases interested in providing anonymized data-sets to the IQDR are welcome to do so, and the list of partner organizations continues to grow yearly.
How is Data Collected?
Data from individual dialysis centres (primary data) is captured via a series of online case-reporting forms. This method of data collection requires local Ethics Board approval and written, informed patient consent. Existing registries or databases can provide de-identified (secondary) data extracts for incorporation into the IQDR. Data-sharing agreements or contracts can be established in order to ensure privacy-rule and other regulatory compliance by both parties. The IQDR Operations Group can provide legal guidance for the negotiation of such contracts, where required.
What is the Process for Joining the IQDR?
Please contact us to discuss enrolment, and to obtain start-up documents.
About this web-site:
This web-site has been designed primarily as a means by which to coordinate communication between participating dialysis centres, sponsoring organizations, and other key stake-holders. It is also hoped that it will be visited by parties interested in participating in the IQDR research agenda, by contributing data, or by designing and executing studies that draw from the IQDR database.
___________________________________________________________________________________
The IQDR is based at the Lawson Health Research Institute, London, Canada.
